- Home
- RGEN
RGEN
Repligen Corporation
as 03-28-2025 4:00pm EST
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.
| Founded: | 1981 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | 9.0B | IPO Year: | N/A |
| Target Price: | $177.78 | AVG Volume (30 days): | 716.8K |
| Analyst Decision: | Buy | Number of Analysts: | 12 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.46 | EPS Growth: | N/A |
| 52 Week Low/High: | $113.50 - $184.98 | Next Earning Date: | 04-30-2025 |
| Revenue: | $634,439,000 | Revenue Growth: | 0.33% |
| Revenue Growth (this year): | 12.02% | Revenue Growth (next year): | 14.99% |
Stock Insider Trading Activity of Repligen Corporation (RGEN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Hunt Anthony | RGEN | Director | Mar 17 '25 | Sell | $151.33 | 26,756 | $4,080,663.26 | 162,997 |
Latest Repligen Corporation News
RGEN Breaking Stock News: Dive into RGEN Ticker-Specific Updates for Smart Investing
StockStory
5 days ago
Winners And Losers Of Q4: IQVIA (NYSE:IQV) Vs The Rest Of The Drug Development Inputs & Services Stocks
Argus Research
5 days ago
RGEN: Lowering target price to $149.00
Insider Monkey
6 days ago
Is Repligen Corporation (RGEN) the Top Stock to Buy According to 12 West Capital Management?
StockStory
10 days ago
Drug Development Inputs & Services Stocks Q4 In Review: Medpace (NASDAQ:MEDP) Vs Peers
Zacks
13 days ago
Ascendis Pharma (ASND) Soars 10.4%: Is Further Upside Left in the Stock?
MT Newswires
13 days ago
Evercore ISI Initiates Repligen at In Line With $155 Price Target
StockStory
14 days ago
Q4 Rundown: PacBio (NASDAQ:PACB) Vs Other Life Sciences Tools & Services Stocks
StockStory
19 days ago
Q4 Earnings Recap: Azenta (NASDAQ:AZTA) Tops Drug Development Inputs & Services Stocks
Compare RGEN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RGEN Repligen Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.